Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when OLMA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOlema Pharmaceuticals reports Q1 2026 financial results
Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read
Key Changes
-
high
Company disclosed first quarter 2026 financial results for the period ended March 31, 2026, via press release. Detailed financial data is contained in the attached exhibit rather than the 8-K body.
Item 2.02 verify on EDGAR → -
low
Filing is a standard quarterly earnings announcement using Form 8-K to furnish the press release as Exhibit 99.1, following routine SEC disclosure practices.
8-K: Earnings view on EDGAR →
Summary
Olema Pharmaceuticals filed an 8-K to announce its first quarter 2026 financial results for the three months ended March 31, 2026. This is a routine quarterly earnings disclosure, with the actual financial data and management commentary contained in the press release attached as an exhibit rather than in the 8-K filing itself. The filing follows standard SEC practice for earnings announcements.
Retail investors should review the attached press release for specific revenue, expense, and cash position details, as well as any updates on the company's clinical pipeline and business outlook. As a biopharmaceutical company, key metrics to watch include research and development spending, cash runway, and progress on clinical trials. The next quarterly report will provide an update on whether the company is meeting its development milestones and managing its cash position effectively.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 12, 2026, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results. The actual financial data is contained in the press release attached as Exhibit 99.1, which is not included in this 8-K body text. This is a standard quarterly earnings announcement filing.
Event · Item 9.01 — Financial Statements and Exhibits
Olema Pharmaceuticals filed an 8-K attaching a press release dated May 12, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release, dated May 12, 2026, of Olema Pharmaceuticals, Inc.
The 8-K discloses that a press release dated May 12, 2026 has been attached as Exhibit 99.1. The filing body itself contains no substantive disclosure about the content or subject matter of the press release, making this a procedural filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify